NRAS StripAssay®
KRAS & NRAS Mutation Detection for Colorectal Cancer
The NRAS StripAssay® identifies a comprehensive group of mutations in the KRAS and NRAS genes, supporting identification of the most effective therapies for patients with metastatic colorectal cancer and enabling avoidance of ineffective EGFR-targeted treatments.
Key Features
NRAS & KRAS Mutation Panel
Comprehensive mutation panel covering both KRAS and NRAS genes for metastatic colorectal cancer profiling.
EGFR Therapy Guidance
Identifies patients who should avoid ineffective EGFR-targeted monoclonal antibody therapies.
Therapy Selection Support
Helps identify patients most likely to benefit from targeted therapies, improving treatment outcomes.
Reverse Hybridization
Based on reverse hybridization of biotinylated PCR products for reliable, parallel mutation detection.
For Research Use Only (RUO)
NRAS StripAssay® is intended for research use only in the United States and is not FDA-cleared for diagnostic use.